Selenomethionine
drugOn this page
Also known as NSC-760370SID50125779SID144206245
Summary
Selenomethionine (CHEMBL113178) is an approved small molecule; indicated across 8 conditions including colorectal adenocarcinoma and follicular lymphoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 8 conditions
- Clinical trials: 11
- Chemistry: 196.12 Da · C5H11NO2Se
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL113178 |
| Name | Selenomethionine |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 105024 |
| ChEBI | CHEBI:30021 |
| Molecular formula | C5H11NO2Se |
| Molecular weight | 196.12 |
| InChIKey | RJFAYQIBOAGBLC-BYPYZUCNSA-N |
SMILES: C[Se]CC[C@@H](C(=O)O)N
IUPAC name: (2S)-2-amino-4-methylselanylbutanoic acid
ChEBI definition: The L-enantiomer of selenomethionine.
Also known as: NSC-760370, Selenomethionine, SID50125779, SID144206245, SELENOMETHIONINE, selenomethionine
Parent form; salt/anhydrous children: CHEMBL1201054
Patent coverage: 5,947 distinct patent families (13,599 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| colorectal adenocarcinoma | 2 | MONDO:0005008 | EFO:0000365 |
| follicular lymphoma | 2 | MONDO:0018906 | MONDO:0018906 |
| Hashimoto thyroiditis | 2 | MONDO:0007699 | EFO:0003779 |
| lung neoplasm | 2 | MONDO:0021117 | MONDO:0008903 |
| colorectal neoplasm | 2 | MONDO:0005335 | MONDO:0005575 |
| clear cell renal carcinoma | 1 | MONDO:0005005 | EFO:0000349 |
| colorectal adenoma | 1 | MONDO:0005484 | EFO:0005406 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 11.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 6 |
| PHASE1/PHASE2 | 2 |
| EARLY_PHASE1 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05363631 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab |
| NCT00526890 | PHASE2 | TERMINATED | Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery |
| NCT00625183 | PHASE2 | TERMINATED | Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma |
| NCT00736164 | PHASE2 | WITHDRAWN | Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer |
| NCT00736645 | PHASE2 | COMPLETED | Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer |
| NCT01682031 | PHASE2 | TERMINATED | Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy |
| NCT02302768 | PHASE2 | UNKNOWN | Effect of Semet (80 and 160 mcg) Versus Placebo in Euthyroid Patients With AIT |
| NCT02535533 | PHASE1/PHASE2 | COMPLETED | SLM + Axitinib for Clear Cell RCC |
| NCT04952129 | PHASE1 | COMPLETED | Optimal Selenium for Bowel Polyps (OSCAR) |
| NCT01211561 | EARLY_PHASE1 | UNKNOWN | Colon Cancer Prevention Using Selenium |
| NCT01112449 | Not specified | COMPLETED | Influence of Selenium on Prostate Cancer Related Biomarkers |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.